CXCL9 and neoplasm: This NE-driven resistance to anti-PD-1 therapy can affect the secretion of C-X-C Motif Chemokine Ligand 9 (CXCL9) and adenosine (ADO) in tumor cells, thereby inhibiting chemotaxis and the function of CD8 T cells.